Document is current
Any future updates will be listed below
-
Authors
Morotti, Matteo https://orcid.org/0000-0002-1790-1185
Grimm, Alizee J. https://orcid.org/0000-0002-4662-5490
Hope, Helen Carrasco https://orcid.org/0000-0001-5583-4510
Arnaud, Marion https://orcid.org/0000-0003-0534-2379
Desbuisson, Mathieu
Rayroux, Nicolas
Barras, David https://orcid.org/0000-0001-8985-4704
Masid, Maria
Murgues, Baptiste
Chap, Bovannak S.
Ongaro, Marco
Rota, Ioanna A.
Ronet, Catherine https://orcid.org/0000-0003-1479-2873
Minasyan, Aspram https://orcid.org/0000-0002-0063-2513
Chiffelle, Johanna https://orcid.org/0000-0002-8312-2681
Lacher, Sebastian B.
Bobisse, Sara
Murgues, Clément
Ghisoni, Eleonora
Ouchen, Khaoula
Bou Mjahed, Ribal
Benedetti, Fabrizio https://orcid.org/0000-0002-9959-9142
Abdellaoui, Naoill
Turrini, Riccardo https://orcid.org/0000-0003-0133-7492
Gannon, Philippe O.
Zaman, Khalil https://orcid.org/0000-0002-2997-527X
Mathevet, Patrice
Lelievre, Loic
Crespo, Isaac
Conrad, Marcus https://orcid.org/0000-0003-1140-5612
Verdeil, Gregory
Kandalaft, Lana E. https://orcid.org/0000-0002-1575-6674
Dagher, Julien https://orcid.org/0000-0003-3864-5149
Corria-Osorio, Jesus https://orcid.org/0000-0001-6844-6170
Doucey, Marie-Agnes
Ho, Ping-Chih https://orcid.org/0000-0003-3078-3774
Harari, Alexandre https://orcid.org/0000-0002-1055-2090
Vannini, Nicola https://orcid.org/0000-0002-6351-7512
Böttcher, Jan P. https://orcid.org/0000-0002-8163-8107
Dangaj Laniti, Denarda https://orcid.org/0000-0002-5659-6427
Coukos, George https://orcid.org/0000-0001-8813-7367
- License Information
-
More Information
Article History
Received: 22 May 2023
Accepted: 26 March 2024
First Online: 24 April 2024
Competing interests
: In the past three years G.C. has received grants, research support or has been coinvestigator in clinical trials by Bristol-Myers Squibb, Tigen Pharma, Iovance, F. Hoffmann-La Roche AG and Boehringer Ingelheim. CHUV has received honoraria for advisory services G.C. has provided to Genentech, AstraZeneca AG and EVIR. Patents related to the NeoTIL technology from the G.C. laboratory have been licensed by the Ludwig Institute, on behalf also of the University of Lausanne and the CHUV, to Tigen Pharma. G.C. has previously received royalties from the University of Pennsylvania for CAR-T cell therapy licensed to Novartis and Tmunity Therapeutics. D.D.L., A.H. and G.C. are inventors on patent applications filed by the Ludwig Institute for Cancer Research (US patent application 63/281,979) pertaining to the subject matter in this Article, and such patent applications have been licensed to Tigen Pharma. P.-C.H. is a co-founder of Pilatus Biosciences and scientific advisor of Elixiron Immunotherapeutics. The other authors declare no competing interests.
